Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Actelion announces “remarkable” PGI2 receptor agonist data

Actelion announces “remarkable” PGI2 receptor agonist data

17th July 2009

Actelion has announced positive data from a study relating to its orally active non-prostanoid PGI2 receptor agonist in patients with pulmonary arterial hypertension (PAH).

In a statement, the organisation explained that the placebo-controlled, double-blind trial, which involved 43 patients, was undertaken to determine the tolerability, safety and efficacy of the therapy.

The company said the study was met with “high statistical significance” and the compound was found to be “well tolerated”.

Commenting, Jean-Paul Clozel, managing director and chief executive of Actelion, said the combination of high efficacy and good tolerability means that the firm is determined to accelerate its development programme for the therapy.

“Together with our partner Nippon Shinyaku, we are very excited by the remarkable results we have seen in this study,” he added.

Earlier this month, the company announced that its paediatric formulation of Tracleer (bosentan) has been approved for the treatment of PAH in children in the EU.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.